Zymark Acquisition Would Enable Caliper Profitability By Year-End 2005
This article was originally published in The Gray Sheet
Caliper's existing distribution channels with diagnostics and life sciences manufacturers such as Bio-Rad and Agilent will remain unaffected by the firm's $72.7 mil. cash and stock purchase of Zymark
You may also be interested in...
While representing a smaller population, the ACTIVATE-T trial targeted patients seen as having greater unmet need.
As a freshman member on the US House Energy and Commerce Committee, former St. Jude Medical exec Rep. Angie Craig can help shape future health care, cybersecurity bills.
The three names under consideration also have a history of focusing on helping underprivileged communities get access to health care.